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887-4 Suboptimal  Platelet Inhibition With Tirof iban in Patients 
Undergoing Coronary Intervention for Unstable Angina 
Daniel Softer, William W. O'Neill, Kishore J. Harjai, Murat Karatepe, Judith Boura, Simon 
R. Dixon, Robert D. Safian, Cindy L, Grines, Jeffrey W. Moses, Issam Mousse, Gary S. 
Roubin, William Beaumont Hospital, Royal Oak, Michigan, Lenox Hill Heart and Vascular 
Institute, New York, New York. 
Background: The current dosing regimen for tirOfiban during percutaneous coronary 
intervention (PCI) is based on limited platelet inhibition (PI) studies using 5pmol o1 ADP 
as a platalet agonist. We hypothesized that, when using 20~mol of ADP, the current 
tirofiban dose may not result in optimal PI in pts undergoing PCI for unstable angina 
(UA). 
Methode: We prospectively measured PI in 102 pte (62 ± 10 yrs, 78% males) who 
received tirofiban (10mcg/kg, 0.15mcg/kg/min) during PCI. All pts received ASA and clo- 
pidogrel prior to the procedure. PI was measured 15 min following tirofiban bolus with the 
IchorTM point-of-care platetet analyzer (Helena Laboratories, Beaumont, TX), using 
20~.mol of ADP. Pts were classified into 2 groups: Gr I-n=61 with stable or class I Breun- 
wald unstable angina (UA) and Gr II-n=41 with class II or Ill UA. 
Results: Gr II pts were more likely to have received b blockers (88 vs 66%, p=0.012), IV 
hepaifn (93 vs 18%, p<0.0001), and to have a recent MI (34 vs 0%, p<0.0001). The 
groups were similar in other respects. PI and % of pts who achieved >70% PI in each Gr 
are shown below. In multivariate analysis, class II or III UA was independently associated 
with <70% PI (OR 11.9, 95%CI 2.5 to 57.3, p=0.002). 
Conclusions: The current dose of tirofiban used in pts undergoing PCI for UA appears 
to be sub-optimal. Our findings may explain the mixed results of recent trials with 
tirofiban in such pts. Large-scale, prospective studies should evaluate whether tirofiban 
dose adjustment will have an impact on clinical outcome. 
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887-5 Tirofiban, Eptifibatide, and Abciximab in Minimizing 
Myocardial Damage During High-Risk Coronary 
Intervention: Final Results of the TEAM Pilot Trial 
Samin K. Sharma, Annapoorna S. Kini, Nohelia Perez, Javed Suleman, Edward A. 
Fisher, Jonathan D. Marmur, Merwin Richard, The Mount Sinai Medical Center, New 
York, New York. 
Background: The diverse results of various randomized PCI trials of GP lib/Ills inhibi- 
tors (GPI) may be due to different levels of platelet inhibiton (PI) achieved by a particular 
GPI agent. TEAM pilot trial is a double blind, randomized study of the three GPI during 
high-risk clinical (rest angina, post MI) or lesion (type C, ostial, calcified, thrombotic, mul- 
tivessel intervention) PCI settings. TEAM study hypothesis was that with similar levels of 
PI (>90%) all three agents will have an equal class effect in reducing myocardial damage 
and 30-day MACE. 
Methods: We analyzed 180 PCI patients randomized to one of the three arms: tirofiban 
(T / RESTORE dose), eptifibatide (E / PURSUIT dose), and abciximab (A / EPILOG 
dose), with similar baseline clinical, angiographic, and procedural characteristics. 
Patients with <90% PI (by RPFA with Ultegra device) after 10 min of GPI infusion, 
received additional half bolus of the blinded agent prior to PCI. 
Results: In 232 lesions treated, angiogrephic success was 97.3% and procedural suc- 
cess 98.9%, 0.5/2.2% major/minor TIMI bleeding complications, 2.2/1.1% mild/severa 
thrombocytopenia nthe entire group and were similar between the three agents. 
Variable Tirofiban Eptifibatide Abciximab p 
n=56 n=61 n=63 
Need for additional bolus (%) 58.9 31.1 53.9 0.004 
Final PI pdor to PCI (%) 93+4 93+3 93_+4 NS 
Any CKMB ^  (%) 15.1 13.9 14.2 NS 
Peak CKMB (U/L) 10.3_+13.2 12.2+21.7 10.7_+11.4 NS 
Peak troponin I ng/mL 4.2_+8.9 3.7_+9.1 5.9_+9.2 NS 
Peak ACT (sac) 248-+22 254_+28 264+16 NS 
30-day MACE (%) 4.7 4.6 4.9 NS 
Conclusion: PCI patients with high-risk clinical/lesions require increased GPI dose com- 
pared to the recommended ose for an optimal PL With this strategy, all three GPI had 
similar effect on myocardial salvage and 30-day MACE and was not associated with 
increase in bleeding. 
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887-6 Initial Experience With a Novel Direct Factor Xa Inhibitor 
in Percutaneous Coronary Intervention 
John H. Alexander, Christopher K. Dyke, Richard C. Becker, Hongqui Yang, Thomas L. 
Robertaon, Satoshi Kunitada, Linda A, Zillman, Eric A. Cohen, Edwin G. Bovill, Peter B. 
Berger, Michael Lincoff, Judith S. Hochman, Paul W. Armstrong, Neal S. Kleiman, Robert 
A. Herdngton, Duke University Medical Center, Durham, North Carolina. 
Background. Anticoagulatlon with unfractlonated heparin in coronary intervention (PCI) 
has significant limitations and upstream inhibition of the coagulation cascade may have 
advantages. We investigated use of a direct factor Xa inhibitor, DX-9065a (DX), in PCI. 
Methods. Patients undergoing elective, native vessel, PCI were randomized (4:1) to 
open label DX or UFH. Using pharmacodynamic modeling, three sequential, weight- 
adjusted, double-bolus and infusion DX regimens were formulated to rapidly achieve and 
maintain plasma concentrations of at least (lower 95% CI) 100ng/ml, 75ng/ml, and 
150ng/ml. UFH was dosed as 70-80 U/kg with, or 100 U/kg without, GP lib/Ilia inhibitors. 
Enrollment in the 75ng/ml phase was discontinued [n=6] after a case of severe intracoro- 
nary thrombus formation. Coagulation parameters were acquired dudng PCI, 15 minutes 
after 2 nd DX bolus. *Present prior to enrollment but extended. Results. Mean age was 58 
years, 82% were male, median PCI duration was 0.3 hours, and 84% and 92% received 
GP lib/Ilia inhibitors and stents. Vessel and lesion sevedty were matched across groups. 
Results are shown in table. Coagulation parameters are median (25 th, 75th). Conclu- 
sions. Direct factor Xa inhibition in PCI using concentration targeted DX-9065a dosing is 
feasible, effective, and provides a measurable anticoagulant effect using bedside INR. 
Further trials 1o define the optimal dose and establish the safety and efficacy of DX- 
9065a in PCI and acute coronary syndromes are needed, 
DX DX DX UFH 
75n~ml 100n~ml 150n~ml n=23 
n=6 n=45 n=45 
Dissection 0 0 2 (4.4%) 0 
Abrupt closure 0 0 0 0 
No reflow 0 0 0 0 
Thrombus 1 (17%) 0 1 (2.2%)* 0 
Side branch loss 0 3 (6.7%) 0 0 
Distal embolization 0 0 0 0 
Major bleed 0 1 (2.2%) 0 0 
Minor bleed 1 (17%) 1 (2.2%) 1 (2.2%) 0 
Transfusion 0 1 (2.2%) 0 0 
Death 0 0 0 O 
MI 1 (17%) 3 (6.7%) 0 0 
Stroke 0 0 0 0 
Revasc 0 0 O O 
ACT (seconds) 149 171 187 NA 
(137,161) (146,188) (150,246) 
n=3 n=8 n=6 
Whole blood 1.9 2.6 3.2 NA 
Bedside INR (1.8,25.5) (2.5,2.7) (3,0,3.2) 
DX-9065a (ng/ml) 123 192 pending NA 
(117,126) (183,250) 
Anti-Xa (IU/ml) 0.33 0.36 pending NA 
(0.26,0.39) (0.32,0.38) 
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888-1 Long-Term Clinical Fol low-Up After Palmaz-Schstz 
Stent Placement In Native Coronary Arteries 
Takeshi Kimura, Kenichi Abe, Yoshihisa Nakagawa, Hiroyoshi Yokoi, Masashi Iwabuchi, 
Naoya Hamasaki, Hideyuki Nosaka, Masakiyo Nobuyoshi, Kokura Memorial Hospital, 
Kitakyushu, Japan. 
Background: Although coronary stenting has been proven to be effective in reducing clin- 
ical cardiac events up to 3 years (yrs), longer-term efficacy and safety have not yet been 
established. Method: To evaluate longer-term (8-11yrs) outcome, follow-up information 
was analyzed in 405 patients (pts) or 424 lesions with clinically successful coronary 
stenting in native coronary artedes (Age; co4~9, Male; 79%, Diabetes; 29%, Multivesset 
disease; 56%, Prior myocardial infarction(MI); 55%, Prior coronary adery bypass sur- 
gery(CABG); 6%, Multivesssl peroutaneous coronary intervention(PCI); 23%, Ejection 
